| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Burrows Scott L is a Chief Financial Officer at Spyre Therapeutics, Inc. with holdings across 2 companies. Recent SEC Form 4 filings include 0 buys and 18 sells.
Estimated insider holdings value: $12.6M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $95.57 | $716,771.00 | -2.5% | - | - | |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $87.74 | $658,039.50 | -3.7% | - | - | |
| Jun 25, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 15,000 | $87.13 | $1,307,000.00 | -6.8% | - | - | |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $71.06 | $532,936.98 | -2.4% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 12,500 | $71.37 | $892,125.00 | -11.3% | +46.2% | - | |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $49.34 | $370,076.00 | -3.7% | +81.6% | - | |
| Mar 3, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 2,500 | $40.65 | $101,620.00 | -1.3% | +83.6% | - | |
| Sep 2, 2025 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sell | 18,428 | $16.26 | $299,639.28 | -15.8% | +72.3% | - | |
| Sep 3, 2024 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sell | 18,531 | $28.17 | $522,073.86 | -13.7% | +3.9% | -36.8% | |
| Mar 6, 2023 | ARQT Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Sell | 291 | $15.26 | $4,441.65 | -0.5% | -41.1% | -25.0% |